25 completed, 4 active not recruiting, 3 terminated, 2 unknown. 12 Phase 2, 7 Not applicable, 7 Phase 1, 7 Phase 3, 4 Phase 4.
Follow Shingles: new trials by email Literature Review of Shingles trials Research Report on Shingles
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Immunogenicity and Safety Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 40 Years and Older Low dose antigen and low dose adjuvant of LYB004, Low dose antigen and high dose adjuvant of LYB004, High dose antigen and low dose adjuvant of LYB004 - Herpes Zoster (HZ), Shingles | Phase 2 | Active not recruiting | Guangzhou Patronus Biotech Co., Ltd. | 840 | 2025-10-23 | 2025-12-30 |
| A Phase 2 Study to Evaluate JCXH-105, an srRNA-based Herpes Zoster Vaccine JCXH-105, Shingrix - Herpes Zoster (HZ), Infectious Diseases | Phase 2 | Active not recruiting | Immorna Biotherapeutics, Inc. | 467 | 2024-10-16 | 2026-11-05 |
| Safety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over Z-1018, Shingrix - Shingles, Herpes Zoster | Phase 1 / Phase 2 | Active not recruiting | Dynavax Technologies Corporation | 764 | 2024-06-17 | 2026-10-16 |
| Nudging Patients to Increase Shingles Vaccination Reminder - Shingles, Vaccination Behavior | Not applicable | Completed | Geisinger Clinic | 50786 | 2024-03-25 | 2026-08-14 |
| A First-in-Human Study to Evaluate JCXH-105, an SrRNA-based Herpes Zoster Vaccine JCXH-105, Active Control (Shingrix) - Herpes Zoster (HZ), Shingles | Phase 1 | Completed | Immorna Biotherapeutics, Inc. | 75 | 2023-05-26 | 2024-09-19 |
| Immunogenicity of Zoster Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Shingrix - Shingles | Phase 2 | Recruiting | Loyola University | 100 | 2023-03-07 | 2023-03-08 |
| A Study to Learn About a Modified RNA Vaccine Against Shingles in Healthy Adults Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection, Candidate 1: PF-07915234: VZV modRNA Suspension for Injection, Candidate 2: PF-07921188: VZV modRNA Suspension for Injection - Shingles, Herpes Zoster Infection | Phase 1 / Phase 2 | Terminated | Pfizer | 484 | 2023-01-25 | 2026-05-04 |
| Immunogenicity of the Recombinant Zoster Vaccine in Multiple Sclerosis Patients recombinant zoster vaccine - Shingles, Zoster | Phase 4 | Unknown | Prof Patrice Lalive | 100 | 2022-12-01 | 2024-04-10 |
| Safety and Immunogenicity of CRV-101 Vaccine for the Prevention of Herpes Zoster in Adults Aged 50 Years and Older Amezosvatein Antigen High Dose Arm A, Amezosvatein Antigen Low Dose Arm B, Shingrix - Herpes Zoster, Shingles | Phase 2 | Active not recruiting | Curevo Inc | 1516 | 2022-02-02 | 2025-09-30 |
| Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers Z-1018, Shingrix - Shingles, Herpes Zoster | Phase 1 | Completed | Dynavax Technologies Corporation | 150 | 2022-01-10 | 2022-11-07 |
| Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and LivER Cancer Epic Healthy Planet Population Health Module - Colon Cancer, Lung Cancer | Not applicable | Completed | University of California, Davis | 20000 | 2020-10-05 | 2023-12-27 |
| Systems Biology of Zoster Vaccine Shingrix® - Zoster, Zoster Varicella | Phase 2 | Completed | Emory University | 38 | 2019-11-14 | 2024-07-30 |
| Treatment of Chronic Postherpetic Pain With Autologous Fat Grafting - A RCT Autologous Fat Grafting / Fat Transplant - Postherpetic Neuralgia, Shingles | Not applicable | Completed | Odense University Hospital | 40 | 2019-09-19 | 2023-03-22 |
| Optimal Timing of Zoster Vaccine After Zoster Illness Zostavax - Shingles | Not applicable | Completed | Seoul National University Hospital | 60 | 2016-03-01 | 2017-10-13 |
| Immune Response to Shingles Vaccination Zoster Vaccine Live - Shingles | Phase 4 | Completed | University of Washington | 10 | 2016-02-01 | 2019-12-05 |
| A Comparative Study of FV-100 vs. Valacyclovir for the Prevention of Post-Herpetic Neuralgia FV-100, valacyclovir - Shingles, Herpes Zoster | Phase 3 | Terminated | ContraVir Pharmaceuticals, Inc. | 237 | 2015-06-01 | 2017-12-22 |
| ZOSTAVAX in Persons Imminently Receiving Chemotherapy for Solid Organ Tumors ZOSTAVAX - Shingles | Phase 4 | Terminated | Louis Stokes VA Medical Center | 22 | 2015-05-01 | 2026-09-23 |
| Comparison of a Live Herpes Zoster Vaccine and a Recombinant Vaccine in 50-59 and 70-85 Year Olds Zostavax, HZ/su vaccine, Placebo - Shingles, Herpes Zoster | Phase 1 | Completed | University of Colorado, Denver | 160 | 2014-05-01 | 2020-07-08 |
| Safety, Tolerability, and Immunogenicity of Zoster Vaccine Live (ZOSTAVAX™) in Healthy Adults in India (V211-025) Zoster Vaccine Live - Herpes Zoster, Shingles | Phase 3 | Completed | Merck Sharp & Dohme LLC | 250 | 2012-10-31 | 2018-09-18 |
| ZOSTAVAX™ (Zoster Vaccine Live) Long-term Effectiveness Study (V211-024) ZOSTAVAX™ - Herpes Zoster, Shingles | Completed | Merck Sharp & Dohme LLC | 1505647 | 2012-05-15 | 2022-07-14 |
Showing 20 of 35. Sign in to see all of them.
Herpes Zoster (35) · Neuralgia, Postherpetic (7) · Chickenpox (6) · Neuralgia (5) · Peripheral Nervous System Diseases (4) · Pain (3) · Communicable Diseases (2) · Herpes Genitalis (2) · Vaccine-Preventable Diseases (2) · Chronic Pain (1) · Colonic Neoplasms (1) · DNA Virus Infections (1) · Health Behavior (1) · Hepatitis C (1) · Herpesviridae Infections (1)
Infections (35) · Varicella Zoster Virus Infection (35) · DNA Virus Infections (34) · Herpesviridae Infections (34) · Virus Diseases (34) · Pathological Conditions, Signs and Symptoms (11) · Nervous System Diseases (9) · Signs and Symptoms (9) · Neurologic Manifestations (8) · Neuromuscular Diseases (8) · Pain (5) · Peripheral Nervous System Diseases (4) · Communicable Diseases (3) · Neuralgia (3) · Behavior (2)
Herpes Zoster Vaccine (12) · Valacyclovir (5) · Capsaicin (2) · FV-100 (2) · Adenosine Monophosphate (1) · Antigens (1) · Injections (1) · Saline Solution (1) · Suspensions (1) · Vaccines, Synthetic (1)
Merck Sharp & Dohme LLC (6) · NeurogesX (3) · Dynavax Technologies Corporation (2) · Emory University (2) · Immorna Biotherapeutics, Inc. (2) · Roxane Laboratories (2) · University of Colorado, Denver (2) · Baylor College of Medicine (1) · Bristol-Myers Squibb (1) · ContraVir Pharmaceuticals, Inc. (1) · Curevo Inc (1) · Geisinger Clinic (1) · Guangzhou Patronus Biotech Co., Ltd. (1) · Kalypsys, Inc. (1) · Louis Stokes VA Medical Center (1)
United States (19) · Australia (2) · China (1) · Denmark (1) · New Zealand (1) · South Korea (1) · Switzerland (1)
Alan Copa, PharmD (2) · Jeffrey Tobias, MD (2) · Nadine Rouphael, MD (2) · Adit A Ginde, MD, MPH (1) · Arnaud Didierlaurent, Pr (1) · Christopher F Chabris, PhD (1) · David H. Canaday, MD (1) · Guy De La Rosa, MD (1) · Jens Ahm Sorensen, Prof (1) · John Sullivan-Bolyai (1) · Lisa Shelton, ARNP (1) · Myron J Levin, M.D. (1) · Patrice Lalive, Pr (1)
PMID 37781954, PMID 18977178, PMID 21087403, PMID 22154769, PMID 22291101, PMID 23908486, PMID 24823623, PMID 26770032, PMID 27943311, PMID 29309521, PMID 30247596, PMID 30600654, PMID 31301920, PMID 31325263, PMID 34850039, PMID 37940142
U19AI090023 (2), K23AG040708 (1)